Drug
Paclitaxel clinical trials
Also written Taxol, BMS-181339, Onxal and DHP107.
Includes 529 studies of Albumin-Bound Paclitaxel, 15 studies of Paclitaxel Liposome and 6 studies of Submicron Particle Paclitaxel Sterile Suspension.
Related medicines add 3 studies
Counted the way a researcher would: Paclitaxel with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Paclitaxel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Paclitaxel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Dec 1992 · TAXOL · NDA 020262 (FDA, Drugs@FDA)
- European Union
- 19 Jul 1999 · Paxene · EMEA/H/C/000216 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
1,744 studies that test it; most in 2015 (78); 4 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1994 | 10 |
| 1995 | 6 |
| 1996 | 20 |
| 1997 | 39 |
| 1998 | 44 |
| 1999 | 58 |
| 2000 | 59 |
| 2001 | 52 |
| 2002 | 35 |
| 2003 | 40 |
| 2004 | 42 |
| 2005 | 54 |
| 2006 | 65 |
| 2007 | 68 |
| 2008 | 73 |
| 2009 | 57 |
| 2010 | 63 |
| 2011 | 53 |
| 2012 | 56 |
| 2013 | 60 |
| 2014 | 73 |
| 2015 | 78 |
| 2016 | 55 |
| 2017 | 65 |
| 2018 | 52 |
| 2019 | 77 |
| 2020 | 66 |
| 2021 | 61 |
| 2022 | 49 |
| 2023 | 50 |
| 2024 | 54 |
| 2025 | 53 |
| 2026 | 56 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 292 · Other 1,463
National Cancer Institute (NCI) (82) · M.D. Anderson Cancer Center (56) · Fudan University (44) · Memorial Sloan Kettering Cancer Center (35) · Gynecologic Oncology Group (32) · Celgene (28) · Alliance for Clinical Trials in Oncology (27) · Eastern Cooperative Oncology Group (24)
Often tested with
Tested in the same studies.
Carboplatin (523) · Gemcitabine (241) · Cisplatin (222) · Bevacizumab (121) · Cyclophosphamide (89) · Doxorubicin (86) · Trastuzumab (76) · Fluorouracil (72)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
- One of Taxoids source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 99 phase 3 studies under way
Paclitaxel is the comparator. A study of two new drugs counts under both.
- 7Sacituzumab tirumotecan · Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · next primary completion Apr 2027
- 5Sacituzumab govitecan · Gilead Sciences, National Cancer Institute (NCI) · next primary completion Feb 2027
- 5Izalontamab brengitecan · Sichuan Baili Pharmaceutical Co., Ltd., Bristol-Myers Squibb · next primary completion Mar 2028
- 4Datopotamab deruxtecan · AstraZeneca · next primary completion Jul 2027
- 4Durvalumab · AstraZeneca · next primary completion Jul 2027
- 4Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion May 2027
- 4Docetaxel · University Hospital Schleswig-Holstein, Fudan University · next primary completion Aug 2028
- 4Mocertatug rezetecan · GlaxoSmithKline, Hansoh BioMedical R&D Company · next primary completion Mar 2027
Reaching primary completion within a year · 99, 10 in phase 3
Studies that test Paclitaxel, phase 3 first.
- Nov 2026A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerPhase 3 · Tata Memorial Hospital
- Dec 2026Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCPhase 3 · Stanford University
- Dec 2026A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerPhase 3 · Mabscale, LLC
- Dec 2026DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyPhase 2/3 · RemeGen Co., Ltd.
- Dec 2026Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal CancerPhase 3 · Karolinska University Hospital
- May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPhase 3 · Akeso
- May 2027International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)Phase 3 · Institute of Cancer Research, United Kingdom
- Jun 2027Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking SurgeryPhase 3 · ARCAGY/ GINECO GROUP
- Jun 2027An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Phase 3 · Hoffmann-La Roche
- Aug 2027Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk WomenPhase 3 · RenJi Hospital
Studies
Open first, then newest update. How each study uses Paclitaxel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,755
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Nab-paclitaxel
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Paclitaxel
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Paclitaxel
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingPhase 1City of Hope Medical CenterNCT06675136Written as Nab-paclitaxel
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerRecruitingPhase 2Loma Linda UniversityNCT03492671Written as nab-paclitaxel
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingPhase 2National Cancer Institute (NCI)NCT04449549Written as Nilotinib and Paclitaxel
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07061977Written as Paclitaxel
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Nab-Paclitaxel
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as nab-paclitaxel
- Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingPhase 2Dustin DemingNCT06493019Written as Paclitaxel
- Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal CarcinomatosisRecruitingPhase 1University of Colorado, DenverNCT07030283Written as Paclitaxel
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingPhase 2Puma Biotechnology, Inc.NCT07465757Written as Paclitaxel
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06601309Written as Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Paclitaxel
- Aspirin and PAClitaxel in Head & Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Washington University School of MedicineNCT07901803Written as Paclitaxel
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerNot yet recruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07900789Written as HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Paclitaxel
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNot applicableHarbin Medical UniversityNCT07552402Written as Oral Paclitaxel Solution Plus Fruquintinib
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT07195734Written as Paclitaxel
- Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker DeclineRecruitingPhase 2Blokhin's Russian Cancer Research CenterNCT07847190Written as Paclitaxel
See all 1,755 studies that test Paclitaxel →
Given beside what is tested · 1,670 — Paclitaxel is usual care or a partner of the new treatment
- DT2216 + Paclitaxel in Platinum-Resistant Ovarian CancerRecruitingPhase 1Elizabeth Stover, MD, PhDNCT06964009Written as Paclitaxel
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as Nab-paclitaxel
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Paclitaxel
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Paclitaxel
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05422794Written as Nab-paclitaxel
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Nab-paclitaxel
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Paclitaxel
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Paclitaxel
- Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 1/2ImunonNCT05739981Written as Paclitaxel
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT05019716Written as Paclitaxel
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Nab-paclitaxel
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Written as Paclitaxel
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025Written as Paclitaxel
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07221474Written as Paclitaxel
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2ExelixisNCT07845786Written as Paclitaxel
- Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingPhase 2Medical University of South CarolinaNCT07720167Written as Paclitaxel
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Paclitaxel
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06952504Written as Paclitaxel
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Paclitaxel
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxel
Showing 20 of 1,670.
As the comparator · 270 — what is tested is compared with Paclitaxel
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Paclitaxel
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Paclitaxel
- A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739199Written as Paclitaxel
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingPhase 3BioNTech SENCT06340568Written as Paclitaxel
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Paclitaxel
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07419295Written as Paclitaxel
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Paclitaxel
- A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07926048Written as Paclitaxel
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnP
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as Paclitaxel
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Paclitaxel
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingPhase 3GlaxoSmithKlineNCT07286331Written as Paclitaxel
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Paclitaxel
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Paclitaxel
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Paclitaxel
- A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line TreatmentRecruitingPhase 3Biokin (Shanghai) Biopharmaceutical Co., Ltd.NCT07518147Written as Paclitaxel
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as paclitaxel
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinRecruitingPhase 3NRG OncologyNCT07441681Written as Paclitaxel
- FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07790380Written as Paclitaxel, Docetaxel, Irinotecan
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Written as Paclitaxel
Showing 20 of 270.
What changed recently
From the registry's own updates since Oct 15, 2026.
Results posted2
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Nov 4, 2026NCT04753879
- Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOct 21, 2026NCT04781088
Stopped1
Newly registered5
- Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal CarcinomaNov 5, 2026NCT07920250
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerOct 28, 2026NCT07900789
- Aspirin and PAClitaxel in Head & Neck Squamous Cell CarcinomaOct 28, 2026NCT07901803
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Oct 16, 2026NCT07877584
Codes
What other systems call Paclitaxel · ClinicalTrials.gg INT008560
- MeSH (NLM) D017239PaclitaxelConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P88XT4IS4DPACLITAXELConfirmed FDA, NLM, Wikidata
- RxNorm 56946Confirmed FDA, Wikidata
- Wikidata Q423762paclitaxelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1411PaclitaxelOne source FDA
- DrugBank DB01229One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017239 | Paclitaxel | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P88XT4IS4D | PACLITAXEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 56946 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423762 | paclitaxel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1411 | Paclitaxel | One source FDA |
| DrugBank | DB01229 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.